- |||||||||| Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - Nov 14, 2018 P3, N=823, Active, not recruiting, Trial completion date: Sep 2018 --> May 2019 | Trial primary completion date: Sep 2018 --> May 2019 Trial completion date: May 2020 --> Mar 2020 | Trial primary completion date: May 2020 --> Mar 2020
- |||||||||| Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - Jul 23, 2018 P3, N=823, Active, not recruiting, Initiation date: May 2018 --> Sep 2018 | Trial primary completion date: Jul 2019 --> Oct 2019 Trial completion date: Feb 2020 --> May 2020 | Trial primary completion date: Feb 2020 --> May 2020
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) - Jun 6, 2018 P2, N=80, Active, not recruiting, Phase classification: P3 --> P2 Trial completion date: May 2018 --> Sep 2018 | Trial primary completion date: May 2018 --> Sep 2018
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date, Combination therapy, Metastases: Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) - Jan 23, 2018 P2, N=80, Active, not recruiting, N=60 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Dec 2017 --> Apr 2018
- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, Combination therapy, Metastases: Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (clinicaltrials.gov) - Apr 6, 2017 P2, N=80, Active, not recruiting, Trial primary completion date: Sep 2018 --> Apr 2017 Recruiting --> Active, not recruiting
- |||||||||| tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion, Trial primary completion date, Combination therapy, Metastases: Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach (clinicaltrials.gov) - Jan 19, 2016 P1/2, N=47, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jul 2015
|